Chang David, Lim May, Goos Jeroen A C M, Qiao Ruirui, Ng Yun Yee, Mansfeld Friederike M, Jackson Michael, Davis Thomas P, Kavallaris Maria
Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
Department of Radiation Oncology, Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia.
Front Pharmacol. 2018 Aug 2;9:831. doi: 10.3389/fphar.2018.00831. eCollection 2018.
Hyperthermia, the mild elevation of temperature to 40-43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.
热疗是指将温度轻度升高至40-43°C，可诱导癌细胞死亡，并增强放疗和化疗的效果。然而，由于其无法有效且优先加热恶性细胞，限制了其作为一种具有临床相关性的治疗方式发挥全部潜力。通过静脉注射靶向肿瘤的磁性纳米颗粒，使其在肿瘤中聚集，随后施加交变磁场以提高肿瘤组织中纳米颗粒的温度，可规避有限的空间分辨率问题。这种靶向方法能够优先加热恶性癌细胞，同时使周围正常组织免受影响，有可能提高热疗的有效性和安全性。尽管临床前研究取得了令人鼓舞的结果，但在该技术进入临床之前，仍有许多挑战需要解决。本文综述讨论了这些挑战，并强调了目前对靶向磁热疗的认识。
